| Cindy Kanegai, | |
|
400 Parnassus Ave, San Francisco, CA 94143-2202 | |
| (415) 476-4854 | |
| Not Available |
| Full Name | Cindy Kanegai |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 16 Years |
| Location | 400 Parnassus Ave, San Francisco, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184919003 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | A111881 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital - Oakland/richmond | Oakland, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
ProMedica, a mission-based, not-for-profit healthcare system focused on improving health and well-being, today announced the finalization of the transaction that adds HCR ManorCare operations to the ProMedica organization.
Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart's MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient's own muscle. MyoCell® has been tested successfully on patients in four clinical trials.
Gilead Sciences, Inc. provided an update today on the development of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride, 25 mg).
The importance of left ventricular diastolic function improvement in patients with heart failure with preserved ejection fraction has been questioned, after researchers found that treatment with spironolactone resulted in some functional improvements but failed to impact on patients' exercise capacity.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond - or not - to immune therapy.
› Verified 2 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
ProMedica, a mission-based, not-for-profit healthcare system focused on improving health and well-being, today announced the finalization of the transaction that adds HCR ManorCare operations to the ProMedica organization.
Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart's MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient's own muscle. MyoCell® has been tested successfully on patients in four clinical trials.
Gilead Sciences, Inc. provided an update today on the development of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride, 25 mg).
The importance of left ventricular diastolic function improvement in patients with heart failure with preserved ejection fraction has been questioned, after researchers found that treatment with spironolactone resulted in some functional improvements but failed to impact on patients' exercise capacity.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond - or not - to immune therapy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cindy Kanegai, 959 Rich Ave, #25, Mountain View, CA 94040-2447 Ph: (310) 709-1402 | Cindy Kanegai, 400 Parnassus Ave, San Francisco, CA 94143-2202 Ph: (415) 476-4854 |
News Archive
ProMedica, a mission-based, not-for-profit healthcare system focused on improving health and well-being, today announced the finalization of the transaction that adds HCR ManorCare operations to the ProMedica organization.
Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart's MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient's own muscle. MyoCell® has been tested successfully on patients in four clinical trials.
Gilead Sciences, Inc. provided an update today on the development of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride, 25 mg).
The importance of left ventricular diastolic function improvement in patients with heart failure with preserved ejection fraction has been questioned, after researchers found that treatment with spironolactone resulted in some functional improvements but failed to impact on patients' exercise capacity.
Scientists led by Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have discovered a gene signature biomarker that may predict which patients will respond - or not - to immune therapy.
› Verified 2 days ago
Dr. Shannon Walker, Hospitalist Medicare: Medicare Enrolled Practice Location: 112 Parnassus Ave Apt 4, San Francisco, CA 94117 Phone: 571-271-8343 | |
Elizabeth A. Andrews, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2200 Ofarrell St, San Francisco, CA 94115 Phone: 415-833-2000 | |
Deborah Chiarucci, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2200 Ofarrell St, San Francisco, CA 94115 Phone: 415-833-2000 | |
Dr. Sneha Kemkar, Hospitalist Medicare: Medicare Enrolled Practice Location: 3700 California St, San Francisco, CA 94118 Phone: 423-309-6170 | |
Dr. Fiona Henderson, Hospitalist Medicare: Medicare Enrolled Practice Location: 3555 Cesar Chavez Street, San Francisco, CA 94110 Phone: 415-647-8600 Fax: 415-641-6823 | |
Todd A. Levine, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2200 Ofarrell St, San Francisco, CA 94115 Phone: 415-833-2000 | |
Jeannie Tran, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-476-7931 Fax: 415-476-4818 |